Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;109(4):336-342.
doi: 10.1111/ejh.13813. Epub 2022 Jun 24.

Survival and risk of vascular complications in myelofibrosis-A population-based study from the Swedish MPN group

Marie Lindgren  1   2 , Björn Andréasson  3 , Jan Samuelsson  4 , Helna Pettersson  3 , Anneli Enblom-Larsson  5 , Anna Ravn-Landtblom  6 , Stefan Scheding  7   8 , Carolina Bentham  9 , Erik Ahlstrand  10
Affiliations

Survival and risk of vascular complications in myelofibrosis-A population-based study from the Swedish MPN group

Marie Lindgren et al. Eur J Haematol. 2022 Oct.

Abstract

Objective: To gain knowledge of underlying risk factors for vascular complications and their impact on life expectancy in myelofibrosis.

Methods: From a cohort of 392 myelofibrosis patients registered in the Swedish MPN registry 58 patients with vascular complications during follow-up were identified. Patients with vascular complications were compared with both 1:1 matched controls and the entire myelofibrosis cohort to explore potential risk factors for vascular complications and their impact on survival.

Results: Incidence of vascular complications was 2.8 events per 100 patient-years and the majority of complications were thrombotic. Patients with complications were significantly older and had lower hemoglobin when compared to the entire cohort. In the case-control analysis, no significant risk factor differences were observed. The major cause of death was vascular complications and median survival was significantly impaired in patients with vascular complications (48 months) compared to controls (92 months). Inferior survival in patients with vascular complications was found to be dependent on IPSS risk category in a Cox regression model.

Conclusion: Vascular complications have a considerable impact on survival in MF. At diagnosis, risk assessment by IPSS does not only predict survival but is also associated with the risk of vascular complications.

Keywords: IPSS; JAK2V617F; Myelofibrosis; myeloproliferative neoplasms; survival; vascular complications.

PubMed Disclaimer

References

REFERENCES

    1. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145-162.
    1. Hultcrantz M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317-325.
    1. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310-2313.
    1. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446-2452.
    1. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.

LinkOut - more resources